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A Ab bs st tr ra ac ct t
Established in 1995, the Hereditary Gastrointestinal Cancer Registry aimed at cancer prevention due to hereditary
colorectal cancer syndromes in Hong Kong through early detection, timely treatment, education and ongoing
research. This article details the history, structure and work of the Registry. A summary is also provided on the
results of various research work conducted by the Registry which facilitates the clinical management of hereditary
colorectal cancer syndromes in Hong Kong Chinese families. 
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I In nt tr ro od du uc ct ti io on n
Hereditary colorectal cancer (HCRC) accounts for
5-10% of all colorectal cancers [1]. In Hong Kong,
colorectal cancer (CRC) is the second most common
malignancy [2]. In a study, our group drew attention
to the distinct epidemiology in the Hong Kong Chinese
population, in which there is an incidence of CRC in
the young population (<50 years of age at diagnosis)
that is four times the rate in other countries, such as
the United States, Scotland and Japan [3]. Subsequent
studies showed that a significant proportion of these
patients actually suffered from HCRC. 
H He er re ed di it ta ar ry y   G Ga as st tr ro oi in nt te es st ti in na al l   
C Ca an nc ce er r   R Re eg gi is st tr ry y
H Hi is st to or ry y
To fill the gaps in our knowledge and service needs,
the Hereditary Gastrointestinal Cancer Registry was
established in Hong Kong in 1995 through the effort
of  a colorectal  surgeon  and  a gastrointestinal
pathologist. The Registry is based at Queen Mary
Hospital, which is one of the teaching hospitals in Hong
Kong where these two doctors work. To the best of our
knowledge, it is the first registry of such kind in China. 
When newly established, the Registry was mainly
supported by research grants, individual donations and
the generosity of the two involved departments at Queen
Mary Hospital. In the past five years, however, the
Registry has been largely supported by the Hong Kong
Cancer Fund, which is a local charitable organisation. 
M Me em mb be er rs s
The Registry is composed of three divisions: clinical,
laboratory and psychosocial teams. 
The clinical team consists of a colorectal surgeon,
a Registry coordinator and a clerical assistant. Apart fromH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 148
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looking after clinical and screening activities, the clinical
team is also responsible for overall administration and
day-to-day running of the Registry. Surgeon liaisons in
other hospitals assist in family recruitment as well as
clinical screening and management. 
The laboratory team consisting of a pathologist,
a scientist and a laboratory technician is responsible
for tissue molecular analysis and genetic testing.
Pathologist liaisons in other hospitals participate in
systemic case finding for hereditary non-polyposis
colorectal cancer (HNPCC) and provide assistance in
tumour tissue tracing. 
The newly established psychosocial team consists
of a clinician (a colorectal surgeon), a part-time clinical
psychologist and a part-time research assistant. In
collaboration with two academic staff (one from the
Department of Social Work and another from the
Department of Psychology) of the University of Hong
Kong, the psychosocial team provides psychosocial
support to recruited families. 
Apart from the provision of service, the three teams
are also active in conducting research in their respective
fields to improve our understanding of Chinese families
with HCRC. 
M Mi is ss si io on n  & &  R Re ec cr ru ui it tm me en nt t
The mission of the Registry is to prevent colorectal
cancer in high-risk families through early detection,
timely treatment, education and ongoing research. Our
service targets are families in Hong Kong suffering or
suspected to be suffering from HCRC syndromes. 
The entry criteria of the Registry are shown in Table 1.
We accept voluntary referrals from both the medical
profession as well as affected families themselves over
the whole territory of Hong Kong. Besides, the Registry
has a research protocol for systemic case finding of
HNPCC conducted in three public hospitals in Hong
Kong. Together, these three hospitals treat about 25%
of all CRC diagnosed in the whole city. For these
hospitals, all resected CRC specimens of patients
diagnosed before 50 years old would be subjected to
microsatellite instability (MSI) analysis. Those patients
with high level of microsatellite unstable (MSI-H) CRC
would be contacted to obtain consent for further analysis
of germline mismatch repair (MMR) gene mutation. 
Up to June 2005, the Registry has recruited 582
families satisfying our recruitment criteria. Four hundred
and forty-three families (76.1%) were referred from 18
public hospitals, among which 327 families (56.2%)
were identified through the systemic case finding
research protocol. Of the remaining, 111 families
(19.1%) were self-referrals and 28 families (4.8%) were
referred by surgeons working in the private sector. 
Based on a combination of clinical and molecular
criteria, we have identified 159 families suffering from
HCRC syndromes. This includes 99 HNPCC families,
51 familial adenomatous polyposis (FAP) families, five
Peutz Jegher's syndrome families and four juvenile
polyposis families. 
Molecular genetic analysis so far has identified 32
families with germline APC gene mutation, 63 families
with germline MMR gene mutation (18 hMLH1, 42
hMSH2 and 3 hMSH6) and four families with germline
T Ta ab bl le e   1 1. .   Entry criteria of the Hereditary Gastrointestinal Cancer Registry
1. Families affected by histologically proven Familial Adenomatous Polyposis (FAP) or other polyposis syndrome. 
This includes index patients and at-risk first-degree relatives above the age of 12 years. 
2. Families affected by Hereditary Non-Polyposis Colorectal Cancer (HNPCC) satisfying the Amsterdam Criteria, the modified 
Amsterdam Criteria and/or with proven germline mismatch repair gene mutation. This includes index patients 
and at-risk first-degree relatives above the age of 25 years. 
3. Suspected HNPCC families satisfying one of the following criteria: 
• An individual has histologically proven colorectal cancer diagnosed before the age of 45 years; 
• An individual has two HNPCC-related cancers, including synchronous and metachronous colorectal cancer 
or associated extra-colonic cancers; 
• An individual has histologically proven colorectal cancer and a first-degree relative has histologically proven colorectal cancer 
or HNPCC-related extra-colonic cancers. At least one of these cancers is diagnosed before the age of 45 years; 
For these families, we recruit both index patients and at-risk first-degree relatives above an age five years younger than 
the youngest age of cancer diagnosis in the family; 
Extra-colonic cancers include: cancers of the stomach, small bowel, uterus, ovary, brain and transitional cell carcinoma 
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Newly Referred Family
Pedigree Establishment
Index Patient Medical Record Tracing & Assessment
Identification of At-Risk FDR
Satisfy Entry Criteria
Family Recruitment
Suspected HNPCC:                             Proven Syndrome Family
Tumour Tissue MSI Analysis                             (FAP/HNPCC) 
MSI-H Cancer
MMR Gene Mutation Analysis Psychoeducational Session: 
– Genetic Testing of Proband 
– Clinical Screening of At-Risk FDR
Pathogenic Mutation Identified for Family
Disclosure of Result
Predictive Genetic Testing of At-Risk FDR
Mutated Gene Carrier                            Genetically Normal
Surveillance Recommendation                   Discharge
and/or Prophylactic Surgery
F Fi ig g. .   1 1. .   Workflow of the Registry for newly referred families
N.S.:FDR – first-degree relative
HNPCC – hereditary non-polyposis colorectal cancer
FAP – familial adenomatous polyposis
MSI – microsatellite instability
MSI-H – high level of microsatellite instability
MMR – mismatch repair 
STK11/LKB1 mutation. Two hundred and twenty-eight
individuals were proven to be mutation carriers in one
of the above-mentioned genes. One hundred and
forty-seven individuals from affected families were
shown  to  be  genetically  normal  and  have  been
discharged from our care. 
R Re ef fe er rr ra al l   W Wo or rk k- -U Up p   & &   M Ma an na ag ge em me en nt t
Figure 1 details the workflow involved for newly
referred families. Trained in pedigree establishment, our
Registry coordinator would contact the family directly to
obtain a detailed family history. A pedigree including
information on at least three generations with maximal
lateral extension would then be established. For cancer
patients in the family, information regarding the type of
cancers,  the  age  at  cancer  diagnosis  and  their
relationship with each other would be obtained. At-risk
first-degree relatives (FDR) would also be identified. 
For those families with histories apparently satisfying
the Registry's entry criteria, consent would be obtained
for recruitment and for tracing the medical record of index
patients for further assessment. In Hong Kong, legislation
requires that a patient's medical record and tissue sample
be kept for seven years only. Therefore, records and tissue
of those cancer patients treated more than seven years
prior to recruitment may not be accessible. Hence, cancer
diagnosis for some families may have to be assumed
without histological confirmation and tissue molecular
analysis for these families may not be possible. 
Counselling will be offered before and after genetic
testing. During counselling, emphasis will be put on.
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the pros and cons of genetic testing. A cooling period
will then be offered before a final decision is made by
an individual regarding genetic testing. Our previous
study on decisional consideration process regarding
genetic testing [4] is helpful in devising counselling
strategy. We found that our Chinese subjects were
relational-orientated, that is, their decision would be
affected more by the well-being of their significant
others than themselves. Hence, emphasis would be
placed  on  the  implication  of  genetic  testing  for
a subject's significant others. 
Clinical surveillance of mutation carriers of various
syndromes are carried out at the referral hospitals or
Queen Mary Hospital depending on the preference of
the subjects as well as their doctors in the referral
hospitals. So far, about 75% of such surveillance
activities have been carried out at Queen Mary
Hospital where the Registry is based. For MMR gene
mutation carriers, the option of prophylactic surgery
instead of continuous clinical surveillance would be
discussed. For those individuals detected to have
cancers upon surveillance or those individuals requiring
prophylactic surgery, the Registry will arrange such
surgical treatment at the respective specialty units. 
C Cl li in ni ic ca al l   R Re es se ea ar rc ch h   o on n   H HN NP PC CC C
C Cl li in ni ic ca al l  P Pr re ed di ic ct to or rs s  f fo or r  M MS SI I  & &  M MM MR R  G Ge en ne e  M Mu ut ta at ti io on n  A An na al ly ys si is s
Relying solely on traditional clinical criteria will
underestimate the incidence of HNPCC in Hong Kong
Chinese. This fact can be exemplified by the results of
one of the Registry's earlier studies [5]: of the 27 patients
with identifiable germline MMR gene mutation, only one
patient's family history satisfied the Amsterdam criteria. 
Because MSI is a hallmark of CRC associated with
MMR defects and it occurs in the vast majority of CRC
in HNPCC [6], we investigated the distinct clinical
features associated with MSI in young (<50 years old)
Chinese CRC patients [7]. We found that the incidence
of MSI increased significantly with decreasing age at
cancer diagnosis: 50% for those <30 years old; 41%
for those 30-39 years old; and 15.1% for those 40-49
years  old  (Armitage  trend  test  p=0.002).  Upon
multivariate analysis, the independent predictors for
MSI were: young age at CRC diagnosis, tumour located
at or proximal to the splenic flexure (that is, proximal
tumour location), increasing number of FDR with CRC
and a personal history of metachronous cancer. 
In a subsequent analysis published in abstract form
on a larger sample of CRC patients (n=333), we found
that 84 (25.2%) of these patients had MSI tumours
among which 39 were caused by germline MMR gene
mutation. While the clinical predictors for MSI were the
same as the previous analysis, we identified the following
as independent clinical predictors of germline MMR gene
mutation: CRC diagnosis before 45 years of age (OR
3.59; 95%CI 1.42-9.07); proximal tumour location (OR
5.05; 95%CI 2.29-11.16); family history of CRC (OR
3.51; 95%CI 1.50-8.20); and family history satisfying
the Amsterdam criteria (OR 14.05; 95%CI 4.37-45.19). 
In another study investigating germline MMR gene
mutation in young CRC patients, we found that the
success rate of mutation detection varied with the strength
of CRC family history [8]. For young patients with MSI-H
CRC but no family history, only 29.4% had identifiable
germline mutation. For those with MSI-H CRC and
a positive family history, the rate of germline mutation
increased to 76.5%. Furthermore, for those with family
histories satisfying the Amsterdam criteria as well as MSI-
H CRC, all had detectable germline MMR gene mutation. 
Knowledge derived from the above three studies
facilitates the Registry in selecting suitable patients for
HNPCC genetic testing. The information also provides
an estimate as to the success rate of such mutation
detection. 
F Fo ou un nd de er r  M Mu ut ta at ti io on ns s  & &  M Mu ut ta at ti io on n  D De et te ec ct ti io on n  S St tr ra at te eg gy y  
Identification of founder mutations has important
implications in the design of a mutation detection
strategy for a particular ethnic population. To date, our
Registry has identified two founder mutations in Hong
Kong Chinese. 
In 2001, we reported a novel germline 1.8 kb
deletion involving exon 11 of hMLH1 gene, which was
often missed by the usual PCR-based mutation detection
method [9]. We devised a diagnostic test based on the
duplex-PCR method to facilitate detection of this mutation.
So far, this mutation has accounted for 11.1% of all
hMLH1 mutations identified by the Registry. 
Last year, we reported on a unique germline MSH2 c.
1452-1455delAATG mutation [10]. To date, this
mutation has been identified in 14 local Chinese
families and it accounts for 33.3% of all hMSH2
germline mutations as well as 22.2% of all germline
MMR gene mutations detected by the Registry. Our
laboratory  has  designed  a specific  PCR-basedH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 151
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diagnostic test on paraffin-embedded tissue to facilitate
mutation detection. 
P Ph he en no ot ty yp pi ic c  F Fe ea at tu ur re es s  o of f  H HN NP PC CC C  P Pa at ti ie en nt ts s  
& &  G Ge en no ot ty yp pe e- -P Ph he en no ot ty yp pe e  C Co or rr re el la at ti io on n
A clinical audit was conducted early this year for 138
proven MMR gene mutation carriers (38 hMLH1, 89
hMSH2 and 11 hMSH6) including 80 men and 58
women from 57 families. The median age at the time of
assessment was 45 years (S.D. 11.3; range 26-80). All
these individuals followed the Registry's recommended
clinical surveillance protocol (see below for details). 
To date, 87 (63%) have developed malignancy, 15
(10.9%) have developed colorectal adenoma only and
36 (26.1%) have had no phenotypic manifestation. Those
who have had malignancy have been significantly older
than those without malignancy (median age 49.5±10.9
years vs. 41.0±8.1 years; p=0.000). Those who have
ever had phenotypic manifestation (cancer or colorectal
adenoma) were also significantly older than those without
phenotypic manifestation (median age 46.0±10.7 years
vs. 39.0±8.1 years, p=0.000). 
CRC developed in 77 individuals and the median
age at first CRC diagnosis was 37.5 years (S.D. 9.6;
range 22-65). Forty-one (53.2%) of these individuals had
their first CRC located at the proximal colon. Ten
individuals (13.0%) had synchronous CRC and another
10 had metachronous CRC. Extra-colonic cancers
developed in 26 individuals (7 men and 19 women).
Gynaecological cancer was the commonest extra-colonic
malignancy and was found in 16 women (27.6%) with
a median age at diagnosis of 43 years (S.D. 6.9; range
29-51). Three women had more than one gynaecological
cancer. The types of gynaecological malignancy were:
10 uterine, 6 ovarian and 3 cervical cancers. For all those
with malignancy, 32 (36.8%) had either synchronous or
metachronous cancers. 
Men  with  HNPCC  were  more  likely  to  develop
malignancy  (70.0%  vs.  53.4%;  OR  2.03,  95%CI 
1.01-4.11), particularly CRC (70.0% vs. 36.2%; OR
4.11; 95%CI 2.01-8.43). However, HNPCC women
were more likely to develop extra-colonic malignancy
(32.7% vs. 8.8%; OR 5.08, 95%CI 1.97-13.13). There
was no difference in the current age and age at cancer
diagnosis between men and women. 
On correlating phenotype with individual MMR
genes,  we  found  that  both  hMLH1 and  hMSH2
mutation carriers were significantly more likely to
develop malignancy than carriers of hMSH6 mutation
(hMLH1 vs. hMSH6: 76.3% vs. 27.3%, OR 8.59,
95%CI 1.87-39.41; hMSH2 vs. hMSH6: 61.8% vs.
27.3%, OR 4.31, 95%CI 1.07-17.39). However, there
was no difference in the age at cancer diagnosis with
respect to the three MMR genes. Furthermore, hMLH1
mutation carriers were significantly more likely to
develop CRC than hMSH6 mutation carriers (68.4%
vs.  37.5%,  OR  5.78,  95%CI  1.30-25.71).  No
significant difference was found in CRC rate between
hMSH2 and hMSH6 mutation carriers. There was no
difference  in  the  age  at  CRC  diagnosis  among
individuals with the three MMR gene mutations. There
was also no difference in the rate and the age at
diagnosis  of  extra-colonic  malignancy  among
individuals with mutation in the three MMR genes,
although the number of affected individuals was small. 
C Cl li in ni ic ca al l  S Su ur rv ve ei il ll la an nc ce e  & &  P Pr ro op ph hy yl la ac ct ti ic c  S Su ur rg ge er ry y  
o of f  M MM MR R  G Ge en ne e  M Mu ut ta at ti io on n  C Ca ar rr ri ie er rs s
The clinical surveillance protocol for our MMR gene
mutation carriers is detailed in Table 2. To date, regular
T Ta ab bl le e   2 2. .   Clinical Surveillance Protocol for Carriers of Germline Mismatch Repair Gene Mutation
S St ta ar rt ti in ng g   a ag ge e   ( (y ye ea ar r) ) I In nt te er rv va al l   ( (y ye ea ar r) ) M Me et th ho od d
colorectal 25 age 25-35:2 years colonoscopy
age >35:1 year
gynaecological 25 age 25-35:3 years vaginal examination, endometrial aspiration,
age >35:2 years trans-abdominal/trans-vaginal ultrasound, 
serum ovarian tumour marker 
urological 25 age 25-35: 3 years urine cytology, ultrasound kidneys & bladder
age >35:2 years
gastric (if positive family history) 25 age 25-35: 3 years upper endoscopy
age >35:2 yearsH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 152
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clinical surveillance of the 138 MMR gene mutation
carriers has detected 12 malignancies in eight subjects.
There were 5 colorectal, 2 urological, 3 uterine, 1 ovarian
and 1 cervical cancers. The majority of these cancers were
detected at an early stage. So far, none of the eight
individuals have died of these surveillance-detected
malignancies. 
Surveillance  colonoscopy  detected  colorectal
adenoma in 46 mutation carriers, including 15 who had
no previous history of malignancy. Twenty of these
individuals had a history of recurrent colorectal adenoma. 
Prophylactic surgery has been performed on 10
mutation carriers. This includes prophylactic colectomy
or completion colectomy in 6 individuals, prophylactic
hysterectomy and bilateral salpingo-oophorectomy
(TAHBSO) in 3 women and simultaneous prophylactic
colectomy and TAHBSO in another woman. 
C Cl li in ni ic ca al l   R Re es se ea ar rc ch h   o on n   F FA AP P
P Ph he en no ot ty yp pe e  & &  C Cl li in ni ic ca al l  M Ma an na ag ge em me en nt t
In a paper published in 2002 on 36 FAP families,
the Registry reported that the strategy of pre-symptomatic
diagnosis by screening and appropriate surgery reduced
the incidence of CRC in FAP patients [11]. In our most
recent update on 51 FAP families, we confirmed the
previous observation. 
This update included 151 documented FAP subjects
(86 men and 65 women) from 51 families including
three families with the attenuated phenotype. Forty-five
of these subjects died before Registry recruitment. 
The diagnosis of polyposis was made by screening
in 58 individuals (30 men and 28 women), whereas the
remaining 93 were diagnosed due to bowel symptoms.
The median age at FAP diagnosis was significantly
younger for those due to screening than those due to
symptoms (28.0±14.0 years vs. 36.0±13.2 years,
p=0.000). Upon diagnosis, 66 (71%) of those with
bowel symptoms had already developed CRC, whereas
only 4 (6.9%) of those diagnosed by screening had
synchronous CRC (p=0.000). Two subjects diagnosed
by  screening  more  than  10  years  ago  refused
prophylactic surgery. Both later presented with bowel
symptoms due to CRC and succumbed to malignancy.
Even with treatment, 56 individuals diagnosed by bowel
symptoms ultimately died from CRC except one. This
gives a CRC mortality rate at 59.1% for this group of
patients. For those diagnosed by screening, three (5.2%)
have died from CRC to date, including the two who
refused prophylactic colectomy. Therefore, the overall
mortality rate was significantly lower for FAP subjects
diagnosed  by  screening  than  those  diagnosed  by
symptoms (5.2% vs. 60.2%, p=0.000). Moreover, the
median age at FAP diagnosis was significantly younger
for those without synchronous CRC than those with
synchronous CRC (29.0±12.6 years vs. 40.0±12.7
years, p=0.000). 
For the type of prophylactic colectomy, restorative
proctocolectomy  (IPAA)  is  the  most  commonly
performed procedure for the classical profuse type of
polyposis, whereas total abdominal colectomy with
ileorectal anastomosis (IRA) is the procedure of choice
for attenuated polyposis. 
Apart from CRC, our FAP subjects are prone to
develop other serious extra-colonic lesions. This can
be illustrated by the clinical data of 106 FAP subjects
(57 men, 49 women) recruited by the Registry up to
June 2005. 
Papillary thyroid cancer is the only extra-colonic
malignancy identified in our subjects to date. Six female
FAP subjects have developed papillary thyroid cancers:
two before and four after the diagnosis of FAP . All
except one of the thyroid cancers developed before
30 years of age. All six women survived after treatment. 
Desmoid tumours occurred in 17 individuals (7 men
and 10 women) at a median age of 36.0 years (S.D. 9.2;
range 21-49) with significant morbidity. Regarding the
location of desmoids, three occurred extra-abdominally,
three were on the abdominal wall, seven were entirely
intra-abdominal and four had both abdominal wall and
intra-abdominal components (combined). 
Two of the intra-abdominal desmoids occurred
without  previous  abdominal  surgery;  one  of  the
desmoids precluded colectomy and another precluded
restorative  proctocolectomy.  For  the  remaining
abdominal desmoids (on the wall or intra-abdominal),
they occurred at a median interval of 2.5 years (S.D.
4.7, range 1-18) after colectomy. 
Regarding  treatment  of  desmoid  tumours,  we
offered surgical resection for extra-abdominal and
abdominal  wall  desmoids.  Two  out  of  three
extra-abdominal desmoids recurred after resection,
whereas all abdominal wall desmoids did not recur. For
intra-abdominal and combined types of desmoids, we
usually adopted conservative treatment which included
expectant treatment and various medical therapiesH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 153
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T Ta ab bl le e   3 3. .   Endoscopic surveillance protocol for patients with familial adenomatous polyposis after prophylactic colectomy
1. Flexible sigmoidoscopy every 6 months after total abdominal colectomy and ileorectal anastomosis. 
2. Pouchoscopy every 2 years after restorative proctocolectomy. 
3. Upper endoscopy and duodenoscopy every 2 years for all patients. 
unless complication occurred. Excision of the abdominal
wall component was performed in one patient with
combined desmoids without recurrence. Debulking
surgery  of  intra-abdominal  desmoids  had  been
performed in three patients resulting in enterocutaneous
fistula in one and recurrence in another two. 
Six patients developed various complications due
to their intra-abdominal desmoids. These complications
and their corresponding treatment include: obstructive
uropathy  in  four  requiring  ureteric  stenting;
uretero-enteric fistula in three requiring ureteric stenting
and long-term prophylactic antibiotics against urinary
tract infection; enterocutaneous fistula in three treated
conservatively; bowel ischaemia in one requiring
massive small bowel resection resulting in short gut
syndrome; intestinal obstruction in one treated by
intestinal  bypass;  and  inferior  vena  caval  (IVC)
obstruction in one requiring IVC stenting. One of these
patients ultimately died of sepsis due to a combination
of short gut syndrome and obstructive uropathy. 
The protocol of endoscopic surveillance for FAP
patients after prophylactic colectomy is detailed in
Table 3. Surveillance endoscopy revealed adenomatous
polyposis in the remaining gastrointestinal tract in
a number of them. Pouch adenomatous polyposis
occurred in five patients at a median interval of 9 years
(S.D. 3.7; range 7-15) after IPAA. Two of these patients
were treated with sulindac (Merck Sharp & Dohme,
Herts, UK) which had resulted in histological resolution
of pouch polyposis in one [12]. 
Gastric and duodenal adenomata were detected in
three and eight patients, respectively. Microadenomatous
changes in the duodenal papilla were detected in 23
subjects at a median age of 35.0 years (S.D. 7.7; S.D.
21-47). The natural history of duodenal microadenoma
and its malignant potential is unknown. In one patient,
serial upper endoscopies documented progression of
duodenal microadenoma to adenoma over five years. 
G Ge en no ot ty yp pe e- -P Ph he en no ot ty yp pe e  C Co or rr re el la at ti io on n
In a previous analysis published in abstract form, we
investigated  genotype-phenotype  correlation  in  54
individuals from 21 FAP families with known APC gene
mutation. We found no difference in the colorectal
phenotype between those individuals with mutation before
and after codon 1000 of the APC gene. After colectomy,
individuals with mutations beyond codon 1000 had
significantly higher incidence of dysplastic changes in the
remaining gastrointestinal tract (23.8% before codon
1000 vs. 76.9% after codon 1000; p=0.004). 
C Co on nc cl lu us si io on n
Establishment of the Hereditary Gastrointestinal
Cancer Registry in Hong Kong allows comprehensive
management of hereditary colorectal cancer syndromes
in a multidisciplinary approach. Apart from contributing
to the understanding of hereditary colorectal cancer in
the Chinese population, the ongoing research of our
group has yielded useful information facilitating clinical
management of Hong Kong families affected by these
complex hereditary syndromes. 
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